Physician profile
John A Millin
NPI 1730182221
$4,710.70
in general payments reported to CMS, 2019-2025
18 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $339 · 2021: $651 · 2022: $433 · 2023: $1,121 · 2024: $960 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,774.85 | 2019-2025 | Hydrus Microstent, Clareon, Argos |
| Ocular Therapeutix, INC. | $123.62 | 2022-2024 | Dextenza |
| Abbvie INC. | $110.50 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $104.90 | 2023 | Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $84.49 | 2024 | |
| Allergan, INC. | $77.34 | 2019-2020 | |
| Omeros Corporation | $74.28 | 2019-2020 | |
| Rxsight INC | $58.77 | 2022 | |
| Dompe US, INC. | $54.40 | 2025 | Oxervate |
| Ivantis, INC | $54.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.45 | 2021-2022 | |
| Sight Sciences, INC. | $37.22 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Genentech USA, INC. | $29.46 | 2025 | Vabysmo |
| New World Medical,INC. | $23.76 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.19 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $14.01 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.18 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Millin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.